Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery

Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Study ID
NCT04067856
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this research is to compare the effectiveness of bevacizumab (Avastin) with another a dexamethasone implant (Ozurdex), with respect to anatomic and visual outcomes as well as injection frequency in subjects undergoing cataract surgery with a concurrent diagnosis of diabetic macular edema (DME).

Key Dates

First listed
Aug 28, 2019
Start date
Jan 1, 2020
Status verified
Feb 2021
Primary completion
Jan 31, 2021
Completion
Jan 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Bevacizumab
    Intravitreal injection of 1.25mg/0.05cc bevacizumab
  • Active Comparator: Dexamethasone implant
    Intravitreal injection of 0.7mg dexamethasone implant

Primary Outcome Measure

Final visual acuity [ Time Frame: 6 month ]

Related Studies